But executives have been uncomfortable about the secondary market that has sprung up to buy shares from current and former Facebook employees because such sales have led to inconsistent valuations of the company that are based on small numbers of shares changing hands.
It's natural for them to expect whatever they can see on a big screen they can see on a small screen, to have access to every bit of information they need in the palm of their hands.
It wasn't until Tarceva extended the lives of patients with non-small cell lung cancer that it became clear that OSI and Genentech actually did have a potential blockbuster on their hands.